GROWTH DISORDERS – A REVIEW ARTICLE

Dr. Shadab Jamal Anwar Iqbal Ahmad Makhdoomi*, Dr. Amjad Kha Saleem Kha Pathan, Dr. Saba Nazli Md. Masood, Dr. Sharique Zohaib and Dr. Sameeroddin Gayasoddin Shaikh

ABSTRACT

Until quite recently, the management of children with growth hormone deficiency (GHD) had focussed on the use of recombinant human GH (rhGH) therapy to normalise final adult height. However, research over the past two decades that has demonstrated deficits in bone health and cardiac function, as well as impaired quality of life in adults with childhood-onset GHD (CO-GHD), has questioned this practice. Some of these studies suggested that there may be short-term benefits of rhGH in certain group of adolescents with GHD during transition, although the impact of GHD and replacement during the transition period has not been adequately investigated and its long-term benefits remain unclear. GH therapy remains expensive and well-designed long-term studies are needed to determine the cost effectiveness and clinical benefit of ongoing rhGH during transition and further into adulthood. In the absence of compelling data to justify widespread continuation of rhGH into adult life, there are several questions related to its use that remain unanswered. This paper reviews the effects of growth hormone deficiency on bone health, cardiovascular function, metabolic profile and quality of life during transition and young adulthood.

Keywords: Growth Hormone Deficiency, Disorder of Growth Hormone.